Baillie Gifford & Co. lifted its position in Aduro Biotech, Inc. (NASDAQ:ADRO) by 30.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 553,090 shares of the biotechnology company’s stock after acquiring an additional 130,390 shares during the quarter. Baillie Gifford & Co. owned 0.74% of Aduro Biotech worth $5,891,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Fox Run Management L.L.C. purchased a new position in Aduro Biotech in the 3rd quarter worth about $127,000. The Manufacturers Life Insurance Company increased its position in Aduro Biotech by 12.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 33,964 shares of the biotechnology company’s stock valued at $388,000 after purchasing an additional 3,769 shares during the period. State Street Corp increased its position in Aduro Biotech by 8.3% during the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock valued at $7,808,000 after purchasing an additional 52,597 shares during the period. Nexthera Capital LP purchased a new position in Aduro Biotech during the 2nd quarter valued at about $1,767,000. Finally, PDT Partners LLC purchased a new position in Aduro Biotech during the 2nd quarter valued at about $570,000. Hedge funds and other institutional investors own 33.63% of the company’s stock.
A number of research firms have commented on ADRO. BidaskClub downgraded shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. HC Wainwright set a $18.00 target price on shares of Aduro Biotech and gave the company a “buy” rating in a research report on Thursday, August 3rd. Canaccord Genuity set a $30.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research downgraded shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, Cowen and Company began coverage on shares of Aduro Biotech in a research report on Tuesday, July 18th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $19.14.
COPYRIGHT VIOLATION NOTICE: “Baillie Gifford & Co. Purchases 130,390 Shares of Aduro Biotech, Inc. (ADRO)” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://ledgergazette.com/2017/11/13/baillie-gifford-co-boosts-holdings-in-aduro-biotech-inc-adro.html.
Shares of Aduro Biotech, Inc. (NASDAQ ADRO) opened at $7.95 on Monday. Aduro Biotech, Inc. has a 12 month low of $6.01 and a 12 month high of $15.52.
Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.03). Aduro Biotech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The business had revenue of $3.79 million for the quarter, compared to analyst estimates of $4.04 million. During the same quarter in the previous year, the firm posted ($0.54) earnings per share. The business’s revenue was up .0% on a year-over-year basis. analysts predict that Aduro Biotech, Inc. will post -1.28 earnings per share for the current fiscal year.
In other news, insider Jennifer Lew sold 6,600 shares of Aduro Biotech stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $11.70, for a total transaction of $77,220.00. Following the completion of the transaction, the insider now directly owns 49,195 shares of the company’s stock, valued at approximately $575,581.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Blaine Templeman sold 2,884 shares of Aduro Biotech stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $11.20, for a total transaction of $32,300.80. Following the transaction, the vice president now directly owns 58,834 shares of the company’s stock, valued at $658,940.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 173,745 shares of company stock valued at $1,782,876. Insiders own 6.60% of the company’s stock.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.